Opthea OPT-302-1002

Status: Enrolling

ClinicalTrials.gov Identifier: NCT02543229

Opthea OPT-302-1002: A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)

Condition: AMD

Study Type: Interventional

Duration: 24 weeks

Eligibility:

  • Ages: 50 years and older
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information, please click here

Go Back
This entry was posted in Uncategorized. Bookmark the permalink.